Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 13/20 | 0.73 |
| ▸ | MME | P08473 | 11/20 | 0.73 |
| ▸ | CPA1 | P15085 | 6/20 | 0.73 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.73 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202567 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL4261778 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30411231 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7685718 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL4261774 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7128864 | 1.00 | ACE (0.73) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29822555 | 0.97 | ACE (0.70) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31089980 | 0.95 | ACE (0.67) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30895730 | 0.94 | ACE (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL7678279 | 0.94 | ACE (0.65) | ACEMMECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | UNIVERSITAT DE BARCELONA (ES) | 2025-11-04 | — | — | US | claimed |
| WO-2025252686-A1 | COMPOUNDS FOR THE TREATMENT OF CANNABIS USE DISORDER | UNIVERSITAT POMPEU FABRA (ES) | 2025-12-11 | — | — | WO | disclosed |
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | UNIVERSITAT DE BARCELONA (ES) | 2025-11-04 | — | — | US | disclosed |
| CN-114641486-B | For reducing CB1Peptide compounds for side effects of receptor agonists | 庞培法布拉大学 | 2025-04-01 | — | — | CN | disclosed |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIVERSITAT POMPEU FABRA (ES) | 2024-02-22 | — | — | US | disclosed |
| CN-114641486-A | For reducing CB1Peptide compounds of side effects of receptor agonists | 庞培法布拉大学 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | CNR2, CNR1, OPRD1 | ACE 1072/4885MME 451/4885CPA1 428/4885 |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | CNR2, CNR1, OPRD1 | ACE 1111/4885MME 379/4885CPA1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.